Literature DB >> 7630625

Treatment of postoperative endophthalmitis.

H Verbraeken1.   

Abstract

Despite many advances in microsurgery, asepsis, antibiotics and intraocular lenses, postoperative endophthalmitis continues to be responsible for the loss of many eyes. In a series of 153 cases of endophthalmitis with a positive culture, 115 occurred after ophthalmic surgery. Eyes appear to be more vulnerable to this complication after extracapsular lens extraction in particular. The analysis of the patients operated for cataract in our own department shows that the incidence of endophthalmitis is 3 times higher in the extracapsular group with lens implantation than in the group of intracapsular lens extraction without lens implantation. Quick diagnosis and prompt action are essential to successful treatment. The treatment consists of vitrectomy and has the following three purposes: (1) provision of a good specimen for direct bacteriological examination and culture; (2) removal of toxins and cells, and (3) creation of space for the injection of an antibiotic. The authors found highly divergent prognoses and bacteriological patterns for endophthalmitis following vitrectomy, bleb surgery and cataract. Similar bacteriological agents do not give rise to the same prognosis after different operations. The post-lens implantation group (88 cases) permitted a distinction to be made between intracapsular and extracapsular surgery. A statistically significantly higher percentage of infection by low-virulence organisms (e.g. Staphylococcus epidermidis) was seen after extracapsular surgery: 60% compared to 30%. The analysis shows that this difference in bacteriological spectrum is the sole explanation for the better functional results following extracapsular surgery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7630625     DOI: 10.1159/000310605

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  10 in total

Review 1.  Uveitis in the elderly--is it easy to identify the masquerade?

Authors:  P Zamiri; S Boyd; S Lightman
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

2.  Penetration of gentamicin and ofloxacin in human vitreous after systemic administration.

Authors:  H Verbraeken; A Verstraete; E Van de Velde; G Verschraegen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

3.  A novel gatifloxacin-loaded intraocular lens for prophylaxis of postoperative endophthalmitis.

Authors:  Mengna Li; Jing-Wei Xu; Jiayong Li; Wei Wang; Chenqi Luo; Haijie Han; Zhi-Kang Xu; Ke Yao
Journal:  Bioact Mater       Date:  2022-06-02

Review 4.  Endophthalmitis after lens extraction.

Authors:  H E Verbraeken
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

Review 5.  Role of inflammation in endophthalmitis.

Authors:  J L Vallejo-Garcia; M Asencio-Duran; N Pastora-Salvador; P Vinciguerra; M R Romano
Journal:  Mediators Inflamm       Date:  2012-09-02       Impact factor: 4.711

Review 6.  Endophthalmitis: state of the art.

Authors:  Kamyar Vaziri; Stephen G Schwartz; Krishna Kishor; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-01-08

7.  Fabrication of nonfouling, bactericidal, and bacteria corpse release multifunctional surface through surface-initiated RAFT polymerization.

Authors:  Bailiang Wang; Zi Ye; Yihong Tang; Yuemei Han; Quankui Lin; Huihua Liu; Hao Chen; Kaihui Nan
Journal:  Int J Nanomedicine       Date:  2016-12-20

Review 8.  Prevention and management of postoperative endophthalmitis: A case-based approach.

Authors:  Lalit Verma; Arindam Chakravarti
Journal:  Indian J Ophthalmol       Date:  2017-12       Impact factor: 1.848

Review 9.  Postoperative Endophthalmitis following Cataract Surgery in Asia.

Authors:  Jin A Choi; Sung Kun Chung
Journal:  ISRN Ophthalmol       Date:  2011-12-25

Review 10.  Recommendations for an expert team investigating a case of cluster endophthalmitis.

Authors:  Shachi R Desai; Purvi R Bhagat; Dipali Parmar
Journal:  Indian J Ophthalmol       Date:  2018-08       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.